Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.
Surrozen has raised $175.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2025.
Surrozen's investors include RA Capital Management, Vivo Capital, Samsara BioCapital, The Column Group, 5AM Ventures.
Surrozen is headquartered in South San Francisco, United States.
Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.
Surrozen is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Surrozen — Funding & Investors." VCBacked, March 24, 2025, https://www.vcbacked.co/company/surrozen. Accessed November 11, 2026.
VCBacked. (2025). Surrozen — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/surrozen
{{cite web |title=Surrozen — Funding & Investors |url=https://www.vcbacked.co/company/surrozen |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Surrozen? Request a listing update